EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV ‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

Robert F Spiera iD, Valerie Devauchelle-Pensec iD, Claire E Owen, Federico Díaz-González iD, Tsutomu Takeuchi iD, Edit Drescher, Jaclyn Anderson, Dilek Arikan, Ronilda D'Cunha, Julie Parmentier, Denise T Kruzikas, Weihan Zhao und 3 weitere

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.43129 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Robert F Spiera und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York. Hauptthemen laut MEDLINE: Polymyalgia Rheumatica, Glucocorticoids, Adalimumab, Antirheumatic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie Inc., AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.

Methods

In this phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study, eligible patients had confirmed PMR, glucocorticoid response and two or more unequivocal PMR flares while tapering glucocorticoids and still on ≥5 mg daily prednisone equivalent. Randomized patients received subcutaneous placebo or ABBV‐154 40, 150, or 340 mg once every other week. The primary efficacy endpoint was time to flare. The sponsor voluntarily terminated the study early.

Results

Overall, 181 patients were randomized (placebo, n = 50; ABBV‐154: 40 mg, n = 42; 150 mg, n = 45; 340 mg, n = 44), and 67.4% completed study drug at week 24. Time to flare was longer for patients receiving ABBV‐154 than those receiving placebo, with Kaplan‐Meier estimate of 24‐week flare‐free rate being lower for placebo. The hazard ratios of ABBV‐154 versus placebo were 0.49 (95% confidence interval [CI], 0.27–0.88), P = 0.017 for 40 mg; 0.44 (95% CI, 0.25–0.79), P = 0.006 for 150 mg; 0.20 (95% CI, 0.09–0.42), P < 0.001 for 340 mg. Incidences of treatment‐emergent adverse events were similar between groups, and the most common across ABBV‐154 cohorts was COVID‐19 (16.0%).

Conclusion

Treatment effects were observed for ABBV‐154 cohorts compared with placebo for time to flare. ABBV‐154 was generally well tolerated. Due to early study termination, results should be interpreted with caution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymyalgia RheumaticaGlucocorticoidsAdalimumabAntirheumatic AgentsImmunoconjugatesHumansDouble-Blind MethodFemaleMaleAgedMiddle AgedTreatment OutcomeAged, 80 and overDose-Response Relationship, DrugAntibodies, Monoclonal, Humanized

Substanzen

GlucocorticoidsAdalimumabAntirheumatic AgentsImmunoconjugatesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York.
  • INSERM U 1227, Brest University Hospital, Brest, France.
  • Austin Clinical School, University of Melbourne, Melbourne, Victoria, Australia.
  • Hospital Universitario de Canarias and Universidad de La Laguna, La Laguna, Spain.
  • Keio University School of Medicine, Shinjuku-ku, Tokyo, and Saitama Medical University, Saitama, Japan.
  • Csolnoky Ferenc Hospital, Veszprém, Hungary.

ORCID-Profile: Robert F Spiera, Valerie Devauchelle-Pensec, Federico Díaz-González, Tsutomu Takeuchi, Frank Buttgereit

Förderung

  • AbbVie Inc.
  • AbbVie

Zitieren

APA

Spiera, R. F., Devauchelle-Pensec, V., Owen, C. E., Díaz-González, F., Takeuchi, T., Drescher, E., Anderson, J., Arikan, D., D'Cunha, R., Parmentier, J., Kruzikas, D. T., Zhao, W., Yang, Y., Stellpflug, K., & Buttgereit, F. (2025). Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV ‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.43129

Vancouver

Spiera RF, Devauchelle-Pensec V, Owen CE, Díaz-González F, Takeuchi T, Drescher E, et al. Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV ‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial. Arthritis & Rheumatology. 2025. doi:10.1002/art.43129

BibTeX
@article{Spiera2025,
  author = {Spiera, Robert F and Devauchelle-Pensec, Valerie and Owen, Claire E and Díaz-González, Federico and Takeuchi, Tsutomu and Drescher, Edit and Anderson, Jaclyn and Arikan, Dilek and D'Cunha, Ronilda and Parmentier, Julie and Kruzikas, Denise T and Zhao, Weihan and Yang, Yang and Stellpflug, Karen and Buttgereit, Frank},
  title = {Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV ‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.43129}
}
Kostenlos starten →